Epidemiologic Study of Patients Registered in Oncology Unit at a Hepatobiliary Tertiary Care Center in India

Abstract

Background: Cancer accounts for about 1 in 7 deaths, worldwide. Primary cancers of the hepatobiliary system are significant health problems worldwide and their management presents great challenges for the hepatobiliary specialist. The incidence of hepatobiliary malignancies is on an increasing trend in India. Study: We did a retrospective study for the epidemiologic, clinical characteristics, and outcomes of patients with cancer registering for treatment in the oncology division at the Institute of Liver and Biliary Sciences, Delhi, India, between January 1, 2017 and December 31, 2017. Results: Atotal of 502 new patients were registered during the study period. The majority of the patients were male (M:F 1.69:1), in the age group of 35–64 years (64.3%) and presented in advanced stages of the disease (72.7% in Stage III and IV). The most common cancers were gallbladder cancer (GBC) (29.7%) and hepatocellular carcinoma (HCC) (17.3%). GBC was the most common in females (M: F 1:1.6), 86.6% were advanced (Stage III and IV), and gallstones were present in 44.3% patients (M: F 1:2.9). Periampullary carcinoma presented in early stages (71% in Stage I and II). Survival at 6 months (n = 110 evaluable patients) was 100% for Stage I, 88% for Stage II, 73.7% for Stage III and 42.1% for Stage IV, and 62.7% overall (P < 0.001). Survival at 6 months (n = 123 evaluable patients) was 56.5% for biliary cancers, 71.4% for HCC, and 75% for nonbiliary cancers (P = 0.15). 217 (43%) patients had one visit to the hospital and 168 (34%) patients had 2–5 visits with no or little follow-up. Conclusions: Most of the disease burden was in the male gender (GBC was more common in females), in the age group 35–64 years and with advanced disease presentation (except periampullary cancer). Survival diminished significantly with increasing stage of disease. Survival was worse for patients with biliary cancers. This could be due to advanced presentation, poor follow-up, and inadequate public health awareness.

Keywords

Epidemiology - gallbladder cancer - hepatobiliary cancers - hepatocellular cancer - periampullary carcinoma

Publication History

Received: 07 September 2018

Accepted: 10 November 2019

Article published online:
28 June 2021

• References

• 1 Available from: https://www.cancer.org/research/cancer-facts- statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. [Last accessed on 2018 Apr 01].
• 2 National Cancer Registry Programme. Hospital Based (2012-2014) and Population Based (2012-2014) Cancer Registry Reports. New Delhi, India: Indian Council of Medical Research; 18, May 2016
• 3 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53
• 4 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
• 5 Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis 2008; 5: A74
• 6 Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225 –235
• 7 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
• 8 Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387: 349-60
• 9 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8
• 10 Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G. et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43
• 11 Starley BQ, Calcagno CJ, Harrison SA. et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51: 1820-32
• 12 Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?. Arch Pathol Lab Med 2008; 132: 1761-6
• 13 Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer 2004; 4: 695-706
• 14 Hundal R, Shaffer EA. Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 2014; 6: 99-109
• 15 Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: Geographical distribution and risk factors. Int J Cancer 2006; 118: 1591-602
• 16 Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II. et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51: 349-64
• 17 Nervi F, Duarte I, Gómez G, Rodríguez G, Del Pino G, Ferrerio O. et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer 1988; 41: 657-60
• 18 Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999; 18: 24-8
• 19 Pilgrim CH, Groeschl RT, Christians KK, Gamblin TC. Modern perspectives on factors predisposing to the development of gallbladder cancer. HPB (Oxford) 2013; 15: 839-44
• 20 Iyer P, Barreto SG, Sahoo B, Chandrani P, Ramadwar MR, Shrikhande SV. et al. Non-typhoidal Salmonella DNA traces in gallbladder cancer. Infect Agent Cancer 2016; 11: 12
• 21 De Aretxabala X, Roa I, Araya JC, Burgos L, Flores P, Wistuba I. et al. Gallbladder cancer in patients less than 40 years old. Br J Surg 1994; 81: 111
• 22 Saika K, Matsuda T. Comparison of time trends in gallbladder cancer mortality (1990-2006) between countries based using the WHO mortality database. Jpn J Clin Oncol 2010; 40: 374-5
• 23 Sinha S, Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet 1978; 147: 929-42
• 24 Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet 1981; 2: 187-9
• 25 Mohandas KM, Patil PS. Cholecystectomy for asymptomatic gallstones can reduce gall bladder cancer mortality in Northern Indian women. Indian J Gastroenterol 2006; 25: 147-51
• 26 Kamisawa T, Tu Y, Kuwata G, Egawa N, Nakajima H, Tsuruta K. Biliary carcinoma risk in patients with pancreaticobiliary maljunction and the degree of extrahepatic bile duct dilatation. Hepatogastroenterology 2006; 53: 816-8
• 27 Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: A relationship revisited. Surgery 2001; 129: 699-703
• 28 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7
• 29 Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10
• 30 Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CMJr. et al. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 2006; 10: 1212-23
• 31 Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J 2012; 18: 485-91
• 32 Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535-45
• 33 Andreotti G, Silverman DT. Occupational risk factors and pancreatic cancer: A review of recent findings. Mol Carcinog 2012; 51: 98-108
• 34 Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT. et al. Alcohol consumption and pancreatic cancer: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23: 374-82
• 35 Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA. et al. Pancreatitis and pancreatic cancer risk: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23: 2964-70
• 36 Huxley R, Ansary-Moghaddam A, Berrington de GonzálezA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-83
• 37 Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W. et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-37
• 38 Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE. et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-72
• 39 Lam KY, Lo CY. Pancreatic endocrine tumour: A 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997; 23: 36-42
• 40 Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A. et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14: 3492-500
• 41 de HerderWW, Kwekkeboom DJ, Feelders RA, van AkenMO, Lamberts SW, van der LelyAJ. et al. Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 2006; 9: 243-8
• 42 Mocellin S, Nitti D. Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n=25 531). Ann Oncol 2013; 24: 3040-4
• 43 Patel T, Sarin YK. Cholangiocarcinoma–controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8: 189-200
• 44 Shukla HS, Sirohi B, Behari A, Sharma A, Majumdar J, Ganguly M. et al. Indian Council of Medical Research. consensus document for the management of gall bladder cancer. Indian J Med Paediatr Oncol 2015; 36: 79-84
• 45 DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD. et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-62
• 46 Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241: 693-9
• 47 Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81